Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020
Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007
The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020
Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020
The cystic fibrosis transmembrane conductance regulator: state of the art Source: Breathe 2008; 5: 163-167 Year: 2008
Late Breaking Abstract: Galectin-3 a key regulator in the development of lung fibrosis Source: Annual Congress 2010 - Stem cells and growth factors in lung injury Year: 2010
Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017 Year: 2018
Late Breaking Abstract: Non-steroid agents for idiopathic pulmonary fibrosis: A systematic review Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010
Late Breaking Abstract - Effects of a new airway clearance technology in children with cystic fibrosis - A homecare randomized controlled trial Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021
Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy? Source: Eur Respir J 2015; 45: 845-848 Year: 2015
Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013
Late Breaking Abstract - Involvement of Orai1 Ca2+ channel in the pathogenesis of pulmonary arterial hypertension. Orai1 as a new potential therapeutic target ? Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021
Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010
Late Breaking Abstract - Short-term effects of a novel bronchial drainage device in Cystic Fibrosis patients Source: Virtual Congress 2021 – What's new in respiratory problems in rare and systemic diseases Year: 2021
Gene therapy for cystic fibrosis: successes and challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79 Year: 2006
Pharmacology and regulation of ENaC function: implication in cystic fibrosis Source: Annual Congress 2009 - Novel regulators of alveolar liquid clearance Year: 2009
A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017 Year: 2018
LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014